Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors

68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives

“…Indeed, at that time (1994) no 68 Ga-labeled pharmaceuticals were in clinical studies, and currently still not one EMA-or FDA-approved 68 Ga-labeled pharmaceutical is available. 20,72 However, as Nunn 84 states, "Molecular imaging must be accepted as not just good science but also as central to routine patient management in the personalized medicine of the future. There is an urgent need to reduce the cost (i.e., time and money) of developing imaging agents for routine clinical use.…”

“…20 Therefore, we will not use that term here. None of the developed 68 Ga-labeled pharmaceuticals has Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval.…”

Study the effect of a pseudo-carrier on pharmacokinetics of 9-fluoropropyl-(+)-dihydrotetrabenazine in rat plasma by ultra-performance liquid chromatography–tandem mass spectrometry

“…One of the most common problems associated with PET imaging agents is an unanticipated or altered absorption, distribution, metabolism, and excretion (ADME) property, there are many factors affecting the ADME property of imaging agents, such as radiopharmaceutical preparation and formulation problems, the patient's own medical problems, and drug interactions [3][4][5]. Up to now, little attention has been devoted to this research field.…”

Influence of sweeteners in the biodistribution of radiopharmaceutical and laboratory tests in rats

“…There are many factors, both external and internal to the body, that may affect the normal biodistribution of radiopharmaceuticals, such as surgical procedures, pathophysiological mechanisms, radiation, infections, smoking (tobacco), use of natural or synthetic drugs and some foods, and nutritional conditions (Barbosa et al, 2009;Bernardo-Filho et al, 2005;Cekic et al, 2011;Holanda et al, 2014;Passos et al, 2002;Valença et al, 2005;Vallabhajosula et al, 2010). Rocha et al (2011), demonstrated that sucralose in different concentrations can change biodistribution of radiopharmaceuticals as sodium pertechnetate in kidney and 99m Tc-DTPA in various organs such as pancreas, stomach, spleen, muscle, and thyroid.…”